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A Novel Murine Cytomegalovirus Vaccine Vector Protects
against Mycobacterium tuberculosis
Peter C. L. Beverley,*,1 Zsolt Ruzsics,†,1 Ariann Hey,*,1 Claire Hutchings,*
Simone Boos,† Beatrice Bolinger,* Emanuele Marchi,* Geraldine O’Hara,*
Paul Klenerman,* Ulrich H. Koszinowski,† and Elma Z. Tchilian*
Tuberculosis remains a global health problem so that a more effective vaccine than bacillus Calmette–Gue´rin is urgently needed.
Cytomegaloviruses persist lifelong in vivo and induce powerful immune and increasing (“inflationary”) responses, making them
attractive vaccine vectors. We have used an m1–m16-deleted recombinant murine CMV (MCMV) expressing Mycobacterium
tuberculosis Ag 85A to show that infection of mice with this recombinant significantly reduces the mycobacterial load after
challenge with M. tuberculosis, whereas control empty virus has a lesser effect. Both viruses induce immune responses to H-2d–
restricted epitopes of MCMV pp89 and M18 Ags characteristic of infection with other MCMVs. A low frequency of 85A-specific
memory cells could be revealed by in vivo or in vitro boosting or after challenge with M. tuberculosis. Kinetic analysis of
M. tuberculosis growth in the lungs of CMV-infected mice shows early inhibition of M. tuberculosis growth abolished by treatment
with NK-depleting anti–asialo ganglio-N-tetraosylceramide Ab. Microarray analysis of the lungs of naive and CMV-infected mice
shows increased IL-21 mRNA in infected mice, whereas in vitro NK assays indicate increased levels of NK activity. These data
indicate that activation of NK cells by MCMV provides early nonspecific protection againstM. tuberculosis, potentiated by a weak
85A-specific T cell response, and they reinforce the view that the innate immune system plays an important role in both natural
and vaccine-induced protection against M. tuberculosis. The Journal of Immunology, 2014, 193: 2306–2316.
T
uberculosis (TB) remains an important cause of morbidity
and mortality worldwide, with 8.7 million new infections and
1.4 million deaths annually, and the difficulty of reducing
this disease burden is compounded by the spread of drug-resistant
organisms and of coinfection with HIV and TB. Furthermore, My-
cobacterium tuberculosis has coexisted with humans for 70,000 y,
giving time for the organism to evolve many immune evasion strat-
egies (1). Nevertheless, vaccination is an attractive containment
strategy for the TB epidemic, but the failure of the recombinant
modified vaccinia Ankara virus booster vaccine, MVA85A, in a recent
phase IIB trial and the relatively poor protection generated by many
candidate vaccines in animal models indicate the difficulties (2–4).
Until now bacillus Calmette–Gue´rin (BCG) has been the only
licensed vaccine for TB, and although vaccine efficacy varies
geographically and protection wanes with age (5), BCG does pro-
tect against tuberculous meningitis (6) and furthermore provides
nonspecific protection against other childhood infections (7). This is
paralleled by the observation that immunization with BCG induces
a state of “trained” immunity in macrophages, increasing the ability
of these cells to respond to diverse pathogens in vitro (8). Thus, the
efficacy of BCG may depend not only on induction of an appro-
priate adaptive response but also on its ability to stimulate the cor-
rect innate response, a property also demonstrated for at least one
experimental TB subunit vaccine (9). Novel vaccine strategies for
TB need to take the importance of innate responses into account.
CMVs are ubiquitous b-herpes viruses that establish life-long in-
fection, associated with low-level persistence within the host. Virus is
shed from epithelial surfaces in body fluids (saliva, urine, breast milk,
and genital secretions) and transmission is by close contact and ex-
posure to these secretions. Infection is acquired most commonly in
infancy or adolescence and is often asymptomatic, although CMVs
can cause life-threatening infection prenatally and in immunosup-
pressed patients (10, 11), and unusually, although the viruses are
highly immunogenic, CMVs can reinfect already infected patients.
CD8 T cell responses to some CMV Ags exhibit “memory in-
flation,” so that instead of an initial response postinfection fol-
lowed by a rapid contraction and maintenance of a smaller memory
population, the responding population increases slowly over time
or is maintained at a high level. Importantly, the responding cells
have an activated effector or effector memory phenotype, which
facilitates entry of the cells into nonlymphoid tissues such as the
lung and genital mucosa (12). These properties have prompted
exploration of CMVs as vaccine vectors against SIV, Ebola virus,
and HSV (13–15). Unusually, one rhesus monkey CMV-based
vaccine vector induces CD8 T cells restricted by MHC class II,
as well as a broad repertoire of T cells specific for many epitopes
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of the vaccine Ags, properties that may account for its efficacy
in protecting against SIV challenge in macaques (16).
The ability to make rCMVs has been facilitated by bacterial
artificial chromosome (BAC) technology, and vaccine vectors have
been constructed expressing Ags under several different promoters.
Furthermore, BAC technology has made it simple to investigate the
function of CMV genes and study the effect of removing those
known to interfere with immune function to improve the protective
efficacy of CMV-based vaccines (17–19).
In the present study, we investigate to our knowledge for the first
time the ability of a novel recombinant murine CMV (MCMV)
vector, in which the first 16 genes of the virus, including some that
interfere with expression of MHC class I having been deleted (17–
20), to induce protective immunity against a bacterial pathogen
M. tuberculosis. Although MVA85A did not show efficacy in hu-
mans (2), recombinant adenoviruses expressing M. tuberculosis
Ag 85A have been shown to protect in mice (21), guinea pigs (22),
and cattle (23), so this well-characterized M. tuberculosis mycolyl
transferase was used as a vaccine Ag in our rMCMV, expressed
under the control of the human CMV promoter.
We show that this recombinant virus, MCMV85A, induces
strong protection against challenge with M. tuberculosis, whereas
the control virus, eMCMV, has a weaker, nonspecific effect. We
examine the mechanisms of protection.
Materials and Methods
Viruses and vector construction
The rMCMV constructs were generated on the Dm1-16-FRT backbone
(24), which is derived from pSM3fr (25) and therefore is m129 negative
(26). This was modified by insertion of an IRES-controlled mCherry
cassette at the 39 untranslated region of the gene M48.5, allowing fluores-
cent detection of viral replication in tissue culture (27). The MCMV85A-
BAC was generated by insertion pO6-A5-CMV-TB85A into the
Dm1-16-FRT-BAC by Flp-mediated recombination as described (28).
pO6-A5-CMV–M. tuberculosis 85A was generated by inserting a PCR-
generated fragment of a codon-optimized synthetic 85A open reading
frame (ORF) fused to the signal sequence of the human tissue plasminogen
activator upstream sequence for better expression in eukaryotic cells
(29), into pO6-A5-CMV-gfp (Sirion Biotech, Martinsried, Germany) using
NheI/NotI digestion to replace the gfp coding sequence. The TB85 ORF
was amplified using primers NTPA forward (59-TCCGCTAGCATG-
GATGCAATGCAATGAAGAGAGGGCT-39) and 85 reverse (59-GATC-
GCGGCCGCGGATCCTAGGCGCCCTGGGGCGCGGGC-39); the re-
striction sites used are underlined. The eMCMV-BAC was generated by
insertion of pO6-A5-CMV into Dm1-16-FRT-BAC. pO6-A5-CMV was
generated from pO6-A5-CMV-gfp by removal of the gfp coding sequence
with NheI/NotI. The viruses MCMV85A and eMCMV were reconstituted
from the respective BACs after transfection of mouse embryo fibroblasts as
described (28).
Adenovirus expressing Ag 85A (Ad85A) is a recombinant human ad-
enovirus type 5 expressing M. tuberculosis Ag85A. The virus was purified
using Adenopure columns (Puresyn, Malvern, PA) and used as a positive
control vaccine (30).
Infectious virus propagation and quantitation
MCMV85A and eMCMV were propagated and titrated in NIH 3T3 cells
(European Cell Culture Collection, Porton Down, U.K.). For propagation,
monolayers of NIH 3T3 cells grown in DMEM (Life Technologies, Paisley,
U.K.) were infected with eMCMV or MCMV85A and incubated for 4 d.
Supernatants were harvested and stored at 280˚C.
To detect expression of 85A in vitro, RNA was isolated from 3T3 cells
infected with MCMV85A 48 h earlier at a multiplicity of infection of 100:1.
Cells were trypsinized, centrifuged, and the pellet was resuspended in 1 ml
TRIzol reagent (Life Technologies). RNAwas extracted using the RNeasy
kit (Qiagen, Hilden, Germany), DNAse treated (DNA-free kit; Ambion/Life
Technologies, Carlsbad, CA), and reverse transcribed using a high-capacity
cDNA reverse transcription kit (Applied Biosystems/Life Technologies,
Foster City, CA) according to the manufacturers’ instructions. PCR was
performed using forward (59-CAGGACGACTTCAGCGGC-39) and re-
verse (59-TCGCCAGCGTCAGCGCCG-39) primers amplifying a 277-bp
product of the 85A sequence (nt 134–411).
Virus titers in organs of eMCMV- or MCMV85A-infected mice were
determined by plaque assay on NIH 3T3 cells as described (31).
MCMV infection and immunization of mice
All animal work was carried out in accordance with the U.K. Animal
(Scientific Procedures) Act 1986 and was approved by the Animal Use
Ethical Committee of Oxford University.
Six- to 8-wk-old female BALB/c mice (Harlan Orlac, Blackthorn, U.K.)
were infected i.p. or i.v. with 2 3 106 PFU eMCMV or MCMV85A. In
some experiments mice were immunized intranasally (i.n.) with 2 3 109
virus particles Ad85A or s.c. with 2 3 105 CFU BCG as described pre-
viously (30).
Isolation of lymphocytes from lungs, spleen, and livers
Lungs were perfused with PBS, cut into pieces, and digested with 0.7
mg/ml collagenase type I (Life Technologies) and 30 mg/ml DNase I
(Sigma-Aldrich, Dorset, U.K.) for 45 min at 37˚C. Digested fragments were
crushed through a cell strainer using a syringe plunger, washed, RBCs
were removed with lysis buffer (Qiagen) and, after centrifugation, resus-
pended in HEPES-buffered RPMI 1640 containing 10% FCS and 1%
penicillin-streptomycin. Spleens were passed through a cell strainer using
a syringe plunger, RBCs were removed with lysis buffer (Qiagen), and the
cells were washed. Livers were passed through a cell strainer, the cells
washed, and lymphocytes were isolated by gradient centrifugation using
Percoll (GE Healthcare, Uppsala, Sweden).
In vitro restimulation of T cells
Splenic lymphocytes from MCMV85A-infected mice were allowed to
adhere to plastic for 2 h at 37˚C in HEPES-buffered RPMI 1640 containing
10% FCS and 1% penicillin-streptomycin. The nonadherent cells were
recovered and mixed 1:1 with naive spleen cells. The mixture was adjusted
to 107 cells/ml and 1 ml was added to 24-well tissue culture plates. Me-
dium or medium containing a pool of 58 peptides (15-mer each) over-
lapping by 10 aa covering the entire 85A sequence was added in 1 ml to
give a final concentration for all peptides of 2 mg/ml. After 4 d culture at
37˚C, 1 ml medium was removed and replaced by medium containing
2 ng/ml recombinant human IL-2 (Life Technologies). After a further 3 d
the nonadherent cells were recovered from each well, washed, and returned
to the same well for overnight culture. The following day the proportion of
Ag-specific cytokine-producing cells in the rested cells was determined by
flow cytometry after restimulation with 85A peptides, as described below.
NK cell assay
YAC-1 NK-sensitive target cells (32) were labeled with CFSE (Invitrogen)
as previously described (30). To 10,000 labeled target cells spleen cells
were added at different attacker/target ratios in round-bottom 96-well
plates and the plates were centrifuged for 3 min at 1500 rpm before in-
cubation for 16 h at 37˚C. The plates were centrifuged again and the su-
pernatant was removed, the cells were resuspended by vortexing, and 50 ml
fixable Live/Dead cell stain was added (Molecular Probes). After 20 min at
4˚C, 100 ml FACS buffer was added to each well, the plate was centri-
fuged, the supernatant was removed, cells were resuspended, and 200 ml
FACS buffer was added. An aliquot of 100 ml was removed from each well
and added to an equal volume of medium containing a known number
(∼104) of fluorescent microbeads. The ratio of viable target cells to beads
was determined by flow cytometry and percentage cytotoxicity calculated
by the formula: % cytotoxicity = 1 2 [(ratio of viable target cells/beads at
each attacker/target ratio)/(ratio of viable cells alone/beads)] 3 100.
Flow cytometry
Lymphocytes were stimulated in RPMI 1640 containing 10% FCS and 1%
penicillin-streptomycin for 6 h with the H-2d–restricted MCMV CD8 peptide
epitopes (SGPSRGRII) from the MCMV M18 (33) or (YPHFMPTNL) from
the pp89 Ag. For Ag 85A, cells were stimulated either with the pool of 58
peptides (15-mer each) or with three H-2d–restricted peptides encoding
the dominant CD4 85A99–118aa (TFLTSELPGWLQANRHVKPT) or CD8
85A70–78aa (MPVGGQSSF) and 85A145–152aa (YAGAMSGL) epitopes (30,
34, 35) (peptides were synthesized at the Weatherall Institute of Molecular
Medicine, Oxford, U.K.). Each peptide was used at 2 mg/ml. After 1 h at
37˚C, GolgiPlug (BD Biosciences, Oxford, U.K.) was added according to
the manufacturer’s instructions.
Cells were washed and incubated with anti-mouse CD16/CD32 (clone
93) to block Fc binding (eBioscience, Hatfield, U.K.). Subsequently, the
cells were stained for CD4 (RM4-5), CD8 (53-6.7) (BD Biosciences),
fixable Live/Dead cell stain (Molecular Probes), IFN-g (XMG1.2), IL-2
(JES6-5H4), TNF-a (MP6-XT22), CD127 (A7R34), CD62L (MEL-14),
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KLRG1 (2F1), and CD27 (LG.7F9) (all eBioscience) using the BD
Cytofix/Cytoperm kit according to the manufacturer’s instructions. Cells
were run on an LSR II (BD Biosciences) and analyzed using FlowJo
software (Tree Star, Ashland, OR). Background responses of unstimulated
cells were subtracted from the stimulated responses.
Infection with M. tuberculosis and determination of
mycobacterial load
MCMV-infected, immunized, or naive groups of four to seven mice were
anesthetized with isoflurane/oxygen and infected i.n. with M. tuberculosis
(Erdman strain) in 40 ml PBS equally divided between both nostrils. Lung
CFU were enumerated 24 h after challenge to determine the number of
organisms deposited (∼200 CFU). Mice were sacrificed at indicated times,
the lungs and spleen were homogenized, and mycobacterial load was de-
termined by plating 10-fold serial dilutions of tissue homogenates on
Middlebrook 7H11 agar plates (E&O Laboratories, Bonnybridge, U.K.).
CFU were counted after 3–4 wk of incubation at 37˚C in 5% CO2. We
have previously shown that i.n. challenge gives identical results to aerosol
challenge with a Henderson apparatus (30).
NK cell depletion
NK cells of naive, eMCMV-infected, or MCMV85A-infected mice were
depleted by two i.p. injections of 50 ml anti–asialo ganglio-N-tetrao-
sylceramide (ASGM1) Ab (Alpha Laboratories) or 100 mg normal rabbit
Ig (Sigma-Aldrich) as a control 4 d before and on the day of M. tuber-
culosis challenge.
NK depletion was assessed by staining of lung and spleen cells for
NKp46 (29A1.4; eBioscience) and DX5 (BD Pharmingen) in addition to
CD4, CD8, and Live/Dead marker. Nondepleted mice were used as control.
Manipulation of IL-21 in vivo
Recombinant IL-21RFc or control human IgG1 (75 mg) (R&D Systems)
was administered i.p. to eMCMV-infected mice 2 d before and on the day
of challenge with M. tuberculosis. Mice were sacrificed 7 d later and
M. tuberculosis CFU were enumerated. Recombinant mouse IL-21 (100 ng
in PBS) (R&D Systems) or CCL22 (R&D Systems) as control was admin-
istered i.n. on the day of M. tuberculosis challenge, mice were sacrificed
7 d later, and M. tuberculosis CFU were enumerated.
Microarrays
Gene expression analysis was performed on purified lungmononuclear cells
of four uninfected and four eMCMV-infected mice 15 d postinfection using
Agilent whole mouse genome oligonucleotide arrays (Miltenyi Biotec).
The raw and normalized microarray data are downloadable from the Gene
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), acces-
sion number GSE57572.
Microarray data were preprocessed using the R language (http://cran.
r-project.org/) and Bioconductor packages (http://www.bioconductor.org/).
Array normalization was performed using the “vsn” algorithm and low
signal features were filtered out from subsequent analysis. The Limma
package was used to infer differentially expressed genes. After p value
adjustment, 338 probes were found significant at p , 0.05.
Statistical analysis
Data were analyzed by one-way ANOVA followed by a Tukey multiple
comparison test.
Results
Generation of rMCMV expressing Ag 85A
The rMCMV constructs were generated by insertion into the Dm1-
16-FRT backbone (24) of an IRES-controlled mCherry cassette at
the 39 untranslated region of the M48.5 gene (27). The MCMV85A-
BAC was generated by Flp-mediated insertion of pO6-A5-CMV-
TB85A, carrying a codon-optimized synthetic TB85A ORF under
the control of the human CMV immediate early promoter
(Supplemental Fig. 1A). The eMCMV-BAC was generated by insertion
of the empty vector. MCMV85A and eMCMV were reconstituted
from the respective BACs after -transfection of mouse embryo
fibroblasts (28). The Dm1-16-FRT–based constructs are derived
from pSM3fr (25) and are therefore MCK-2 (m129) negative (26).
Additionally, the constructs lack genes m01–m16. This region
includes two of the three MCMV genes, m04 and m06, which
downregulate MHC class I–mediated Ag presentation, whereas
m152 is intact. The replication of Dm1-16-FRT–derived con-
structs has been studied extensively in tissue culture where they
replicate with wild-type kinetics (24, 27, 36).
Expression of the 85A gene was assessed by RT-PCR analysis
of NIH 3T3 cells infected with eMCMV or MCMV85A. Only
MCMV85A-infected 3T3 cells generate a PCR product consistent
with the expression of 85A RNA in the cells (Supplemental Fig.
1B). To ensure that the rMCMVs had comparable growth char-
acteristics, virus growth was assessed after in vivo infection in the
salivary glands, liver, and spleens of mice at 6 d postinfection.
Supplemental Fig. 1C shows that eMCMV and MCMV85A rep-
licate comparably, suggesting that the insertion of 85A does not
interfere with viral replication in vivo.
MCMV85A protects against pulmonary challenge with
M. tuberculosis
To determine the efficacy of eMCMVand MCMV85A in protection
against M. tuberculosis challenge, BALB/c mice were infected i.p.
with 2 3 106 PFU eMCMVor MCMV85A and 4, 8, 12, or 24 wk
later challenged with M. tuberculosis. Mice were also infected i.v.
and challenged 4 wk later. Controls were either uninfected or im-
munized with Ad85A i.n., a highly protective subunit vaccine in this
mouse strain, or BCG s.c. (21, 30). The mycobacterial load in the
lungs and spleens was determined 5 wk after M. tuberculosis chal-
lenge. Although the i.v. route induced better protection at 4 wk after
MCMV infection, because MCMV virus stocks produced in vitro are
of low titer it is difficult to give the volumes required for high doses
by the i.v. route, so the i.p. route was used for further analysis.
Irrespective of the route of infection, at all times after MCMV85A
infection, there is a significant reduction in mycobacterial load in the
lungs compared with naive animals. At 4 wk there is significantly
greater protection in MCMV85A i.v. infected than in eMCMV i.v.
infected animals. At 8 wk the reduction in MCMV85A i.p. infected
mice is comparable to that found in Ad85A i.n. immunized animals
assayed simultaneously and at 12 wk to BCG. As in Ad85A-
immunized mice (30), protection is maintained for at least 24 wk
in MCMV85A-infected mice (Fig. 1). eMCMV-infected animals
almost always show a trend toward a reduction in lung mycobac-
terial load, but this does not reach statistical significance in the
experiments shown. Splenic CFU show similar trends to the lungs
(not shown).
These results indicated that MCMV85A induces protection
against M. tuberculosis, sustained for at least 24 wk and compa-
rable to that obtained with the most effective subunit vaccine,
Ad85A delivered i.n., or BCG, the “gold standard” TB vaccine.
MCMV-specific immune responses
Because it is difficult to detect even wild-type MCMV beyond
the first few weeks after infection in vivo in mice (37, 38), we
studied the immune response to well-characterized H-2d–restricted
MCMV antigenic epitopes to determine whether the attenuated
eMCMV or MCMV85A viruses persist in vivo and generate im-
mune responses characteristic of other MCMVs.
The H2-Ld–restricted CD8 T cell response to the immunodominant
epitope (amino acid YPHFMPTNL) from the IE1 protein m123/
phosphoprotein 89 (pp89) (39) shows an initial peak at day 9 after
MCMV infection followed by a decline. However, after day 30, pp89-
specific T cell frequencies rise again so that at day 180 postinfection
∼5–8% of the CD8 cells in the lung, ∼1% in the spleen, and ∼6% in
the liver are pp89 specific (Fig. 2A). In contrast, the H2-Dd–restricted
CD8 response to an epitope (amino acid SGPSRGRII) from the M18
early gene (33) peaks at day 9 followed by a decline, with frequencies
at day 180 of M18-specific cells remaining detectable at ∼1.7% in
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the lung, ∼1% in the spleen, and 0.5% in the liver (Fig. 2B). There
are no significant differences between the frequencies and kinetics
of pp89- (Fig. 2A) or M18-specific (Fig. 2B) cells in eMCMV-
versus MCMV85A-infected animals.
We also determined the differentiation and activation status of
pp89- and M18-specific CD8 T cells, using CD127 and CD62L to
define memory subpopulations (Supplemental Fig. 2) and increased
KLRG1 and decreased CD27 to define the extent of activation
(Supplemental Fig. 3) among the Ag-specific cells of MCMV85A-
or eMCMV-infected mice. At 60 d postinfection with MCMV85A,
in the lungs ∼61% of pp89-specific cells are effectors compared
with 28% of M18-specific cells, whereas 57% of M18-specific and
37% of pp89-specific cells are effector memory. Similar trends are
seen for eMCMV at day 60 and for both viruses at day 180 (data
not shown). At both time points, pp89-specific cells show increased
KLRG1 and decreased CD27 Ag expression (40) compared with
M18-specific cells, and also lung and liver Ag-specific cells are
more activated than splenic cells (Supplemental Fig. 3).
The kinetics of the pp89 and M18 responses confirm their infla-
tionary and noninflationary nature, respectively. In agreement with
previous studies, pp89-specific cells exhibit a more activated phe-
notype than do M18-specific cells, especially in the lungs and liver.
Overall, these data indicated that the two vectors persist in vivo,
behave similarly to previously describedMCMVs, and induce similar
responses to MCMVAgs at the time points tested (39, 41, 42).
Ag 85A–specific responses
We next assessed the response to Ag 85A in the MCMV85A-
infected animals. A pool of 58 peptides (15-mer each), covering
the whole sequence of 85A protein, was used to stimulate lung,
liver, and spleen cells fromMCMV85A- or eMCMV-infected mice
for 6 h in vitro, and intracellular staining for IFN-g, TNF-a,
and IL-2 was performed but we could not demonstrate convinc-
ingly a reproducible, continuing, and statistically significant 85A-
specific response at 3, 6, 9, 30, 60, or 180 d postinfection. Neither are
cytokine-producing cells from MCMV85A-infected mice demon-
strable when individual known dominant H-2d–restricted peptide
epitopes of Ag 85A (I-Ed CD499–118, L
d CD870–78, and K
d CD8145-152)
(34, 35) are used for stimulation. Furthermore, no T cell response
to 85A can be detected by ELISPOT, nor is 85A-specific Ab de-
tectable by ELISA in sera from MCMV85-infected animals (data
not shown).
However, because the MCMV85A animals were better protected
than eMCMV-infected mice, we reasoned that there must be an
85A-specific response and that it should be possible to reveal
this by boosting in vivo or in vitro. Therefore, 4 wk after infection
with either eMCMVor MCMV85A, we boosted the animals with
Ad85A and examined the immune response 6 d later. At this early
time after immunization, eMCMV-infected mice make a very small
response to Ag 85A, but the response in MCMV85A-infected
mice is much greater (Fig. 3A). Similarly, when spleen cells from
MCMV85A are stimulated with 85 peptides in vitro in the pres-
ence of uninfected APCs and expanded in IL-2, a population of
Ag-specific CD8 T cells can be detected (Fig. 3B).
In BALB/c mice after Ad85A immunization most of the CD8
responding cells react to the dominant 85A70–78 epitope and a
smaller proportion to the 85A145–152 epitope. There is also a
small but detectable CD4 response to the 85A99–118 epitope (40).
FIGURE 1. Protection against M. tuberculosis challenge. BALB/c mice were infected with 2 3 106 PFU eMCMVor MCMV85A i.p. or i.v. and 4 wk
later challenged with M. tuberculosis. Mice challenged at 8, 12, and 24 wk postinfection were immunized i.p. Controls were naive or immunized with 2 3
109 virus particles Ad85A i.n. or 2 3 105 CFU BCG s.c. LungM. tuberculosis CFU were enumerated 5 wk after challenge. Symbols show individual mice,
and the horizontal line indicates the mean. Data were analyzed by a one-way ANOVA with a Tukey posttest.
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In MCMV85A-infected mice boosted with Ad85A, responses to
the CD8 dominant and subdominant epitopes are seen whereas the
CD4 response is unchanged (Fig. 3C). In vitro–boosted and IL-2–
expanded cells from MCMV85A-immunized animals show simi-
lar specificity (data not shown). Data on CD8 IFN-g and CD4 IL-
2–producing cells are shown, as these provide the most sensitive
detection of the two subsets.
Overall, these results show that MCMV85A-infected animals
have a low frequency of 85A-specific memory CD8 and CD4
cells, which can be revealed by boosting with Ad85A in vivo or
with 85A peptides in vitro.
Mechanism of protection against M. tuberculosis
In most experiments eMCMV-infected animals show lower CFU
than do naive animals, although this seldom reaches statistical
significance (see Fig. 1). However, because the 85A-specific re-
sponse is consistently low and yet protection by MCMV85A is
equivalent to BCG and Ad85A i.n., two highly effective vaccines
in mice, we wanted to better establish the mechanisms of pro-
tective immunity againstM. tuberculosis in MCMV-infected mice.
As we have previously shown that pulmonary local immune re-
sponses can inhibit M. tuberculosis growth very early after chal-
lenge, whereas systemic immune responses act only later (30), we
first determined the kinetics of M. tuberculosis growth in the lungs
of mice challenged with M. tuberculosis 5 wk postinfection with
eMCMVor MCMV85A. Groups of mice were sacrificed 7 and 15 d
later to determine the mycobacterial load in the lungs (Fig. 4A).
Both eMCMV and MCMV85A animals show a reduction in
mycobacterial load at 7 and 15 d after challenge (Fig. 4A). The
early reduction of M. tuberculosis load in eMCMV mice suggests
that MCMV infection on its own induces early acting nonspecific
protection against M. tuberculosis, potentiated by the specific re-
sponse to 85A in MCMV85A mice. Because MCMV has been
shown to activate NK cells, we used anti-ASGM1 Ab, given 4 d
before and on the day of M. tuberculosis challenge, to deplete NK
cells from naive, eMCMV-infected, or MCMV85A-infected mice.
NK depletion alone does not affect M. tuberculosis CFU in the
lungs of naive mice at 7 d after challenge, whereas it reverses the
early protective effect in eMCMV- and MCMV85A-infected mice
(Fig. 4B). Staining with DX5 and NKp46 Abs confirms the de-
pletion of NK cells (Fig. 4B). In the experiment shown, a control
Ab was not administered but a repeat experiment included con-
trol rabbit Ig. Identical results were obtained and control Ig
had no effect. Although NK depletion abolishes protection in both
eMCMV- and MCMV85A-infected mice, the latter show more
effective control of M. tuberculosis at both 7 and 15 d (Fig. 4A),
suggesting that an Ag-specific response potentiates the NK effect.
We therefore analyzed Ag-specific responses of lung cells of
eMCMV- and MCMV85A-infected mice 15 d afterM. tuberculosis
challenge. Only the MCMV85A mice show an 85A-specific lung
FIGURE 2. Kinetics of pp89 and M18 responses. BALB/c mice were infected with 23 106 PFU eMCMVor MCMV85A i.p. Lung, liver, and spleen cells
were isolated at the indicated times and after stimulation for 6 h with pp89 (A) or M18 (B) peptides, and the proportion of CD8 IFN-g–producing cells was
determined by surface and intracellular immunofluorescence staining and flow cytometric analysis. Results are expressed as the means 6 SD of three to
four mice per group.
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CD8 response (Fig. 4C), whereas a pp89-specific response is
detected in both eMCMV- and MCMV85A-infected mice. As
previously shown by others, all M. tuberculosis–challenged mice
make a CD4 response to the pool of 85A peptides (34, 35).
FIGURE 3. Ag 85A–specific immune responses. (A) Mice were infected with eMCMV or MCMV85A and 4 wk later boosted with 2 3 109 virus
particles Ad85A i.m. Six days later, lung, spleen, and liver cells were isolated and stimulated for 6 h with pooled 85A peptides. (B) Spleen cells from
eMCMV- or MCMV85A-infected mice were stimulated in vitro with a pool of 15-mer peptides covering the sequence of Ag 85A, expanded with IL-2,
rested, and restimulated with 85A peptides before assaying by intracellular staining and flow cytometry for Ag-specific IFN-g–producing cells. (C) Lung
or spleen cells from MCMV85A-infected mice boosted with Ad85Awere stimulated with individual 85A peptides covering the dominant H-2d CD4 and
CD8 epitopes. The frequencies of IFN-g– or IL-2–producing cells were determined by flow cytometry on CD8- and CD4-gated cells. Results are
expressed as the means 6 SD of three or four mice per group, representative of two independent experiments. Data were analyzed by a one-way ANOVA
with a Tukey posttest.
The Journal of Immunology 2311
Taken together, these data indicate that MCMV on its own has
an early effect on mycobacterial growth, mediated mainly by NK
cells, but the low frequency of 85A-specific memory cells present
in MCMV85A-infected mice contributes to significantly improved
protection.
However, depletion of ASGM1-expressing cells is known to
affect more than just NK cells (43, 44), so we sought further ev-
idence for the role of these cells and carried out a microarray
comparison of gene expression in the lungs of naive and eMCMV-
infected animals (Supplemental Fig. 4). Microarray data were
deposited in the Gene Expression Omnibus database (http://www.
ncbi.nlm.nih.gov/geo/), accession number GSE57572. IL-21 ex-
pression, a cytokine known to be related to NK cell activity, is
highly upregulated in eMCMV versus naive mice. Quantitative
RT-PCR confirmed the upregulation of IL-21 message (IL-21
mRNA relative to hypoxanthine phosphoribosyltransferase in na-
ive lungs of 0.00036 versus eMCMV lungs of 0.015, p = 0.02).
We assessed the importance of IL-21 in two ways. First, we ad-
ministered a soluble rIL-21RFc construct (45) systemically to
MCMV-infected mice at the time of M. tuberculosis challenge to
block IL-21 activity, and second, we tested whether rIL-21 ad-
ministered to the lungs could induce early inhibition of M. tu-
berculosis growth. The results of these experiments are shown in
Fig. 5. IL-21RFc blocks the early inhibitory effect on M. tuber-
culosis growth seen in eMCMV-infected mice (Fig. 5A), whereas
IL-21 induces growth inhibition in normal mice (Fig. 5B), sug-
gesting that IL-21 plays an important role in the nonspecific
protective effect seen in eMCMV-infected mice, most likely
through activation of NK cells (46, 47). In vitro assay of spleen
cells from eMCMV mice confirms increased NK killing activity
on YAC-1 cells compared with naive mice (Fig. 5C).
Discussion
In many species, CMVs establish largely asymptomatic persistent
infection, characterized by the accumulation of large numbers of
virus-specific T cells (memory inflation) (39). These properties, as
well as the fact that infection does not prevent reinfection, make
rCMVs attractive vaccine vectors and they have been shown al-
ready to induce robust protection against SIV challenge in mac-
aques and Ebola virus or HSV in mice (13–15). In this study,
FIGURE 4. Mechanisms of M. tuberculosis protection. (A) Mice were infected with 2 3 106 PFU eMCMVor MCMV85A i.p. with uninfected (naive) mice
as controls. Five weeks postinfection all the mice were challenged with M. tuberculosis and sacrificed at days 7 and 15 for enumeration of lung CFU. (B) Five
weeks postinfection with eMCMV or MCMV85A, infected and control uninfected (naive) mice were challenged with M. tuberculosis i.n. and after 1 wk
sacrificed for enumeration of lungM. tuberculosis CFU. The day before and on the day ofM. tuberculosis challenge, mice were given anti-ASGM1 Ab i.p. Flow
cytometry panels show depletion by anti-ASGM1 Ab as assessed by DX5 and NKp46 staining of lung cells. Representative CFU data from one of two
experiments with four to five mice per group are shown. (C) Mice were infected and challenged as in (A). Lung cells were isolated 14 d after theM. tuberculosis
challenge and stimulated for 6 h with pooled 85A peptides or pp89. The frequencies of IFN-g–producing cells were determined by flow cytometry on CD8- and
CD4-gated cells. Results are expressed as the means 6 SD of four mice per group. Data were analyzed by a one-way ANOVA with a Tukey posttest.
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to our knowledge, we show for the first time that an rMCMV
expressing M. tuberculosis Ag 85A confers protection against
M. tuberculosis challenge in BALB/c mice. The reduction in myco-
bacterial load achieved by MCMV85A is comparable to that in-
duced by Ad85A administered i.n. as well as the gold standard
vaccine, parenteral BCG (21, 30, 48). Both MCMV85A and
Ad85A induce protective immunity maintained for at least 24 wk
(Fig. 1) (30).
Surprisingly, an immune response to Ag 85Awas not detectable
ex vivo in MCMV85A-infected mice and could be demonstrated
only after in vivo boosting with Ad85A, following M. tuberculosis
challenge or after in vitro stimulation in the presence of uninfected
APCs, indicating that the MCMV85A-infected animals do have
85A-specific memory cells, but at a frequency not reliably de-
tectable by intracellular cytokine staining. We considered several
explanations for the low response to 85A. The first was that these
vectors do not productively infect mice or persist in vivo. How-
ever, the vectors replicate in vitro similarly to wild-type MCMV
(24, 27, 49) and they are capable of productive infection in vivo.
Furthermore, they induce typical inflationary and noninflationary
responses against pp89 and M18 epitopes. Because tissue culture
grown MCMV is difficult to detect in vivo after the first few weeks
of infection in immunocompetent mice (37) (so called “molecular
latency”), virus can often only be revealed by transfer of tissues
to SCID recipients. Therefore, persisting and inflating immune
responses are commonly taken to indicate persistent infection
(reviewed in Ref. 38), indicating that eMCMV and MCMV85A
persist in vivo, as do similar attenuated MCMVs (49, 50). Another
explanation for the low frequency of the 85A response might be
antigenic competition between the dominant CD8 Ld-restricted
85A70–78 epitope and the L
d-restricted inflationary pp89 epitope.
MCMV85A lacks the first 16 genes of the MCMV genome, in-
cluding the m04 and m06 genes responsible for downregulation
of MHC class I (17–20), so that presentation of MHC class
FIGURE 5. Effect of IL-21 on M. tuberculosis pro-
tection. (A) Mice infected with 2 3 106 PFU eMCMVor
uninfected controls were challenged withM. tuberculosis.
Two days before and on the day of challenge, half of each
group was treated with 75 mg IL-21RFc i.p. Mice were
sacrificed 7 d later and M. tuberculosis CFU were enu-
merated. Human IgG1 was used as a control and had no
effect (data not shown). (B) Naive mice were challenged
with M. tuberculosis. On the days of challenge 100 ng
recombinant mouse IL-21 or 100 ng CCL22 as control
was administered i.n. Mice were sacrificed 7 d later and
M. tuberculosis CFU were enumerated. (C) Spleen cells
from five eMCMVand five uninfected mice were assayed
on YAC-1 targets for NK activity. Data from 100:1 spleen
cell to YAC-1 ratio are shown. Horizontal lines show the
mean of each group. Data were analyzed by a one-way
ANOVA with a Tukey posttest.
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I–restricted epitopes should not be inhibited in MCMV85A-infected
cells because of the abundance of class I. However, m152, which
is intact in this backbone, can downregulate Dd and Ld (19) and
might potentiate competition, although both pp89 and 85A should
be expressed with immediate early kinetics and should therefore
be less sensitive to interference by the early gene m152 (38).
Nevertheless, the possibility of antigenic competition for Ld is
supported by data on the response to another Ld-restricted epitope,
M83/pp105, which is also maintained at a very low frequency,
close to the limit of detection of intracellular cytokine staining
(39). Thus, it may be that the pp89 epitope outcompetes other Ld-
restricted epitopes irrespective of the abundance of MHC class I,
either because it has higher affinity for Ld or through other un-
determined viral mechanisms.
The CD8 response in MCMV85A-infected animals, detected
after boosting with Ad85A in vivo or with 85A peptides in vitro, is
directed to MHC class I–restricted epitopes previously reported in
animals immunized with Ad85A, 85A protein, or peptides (34,
35). There is no evidence for the unconventional MHC class II–
restricted CD8 responses generated by recombinant rhesus mon-
key CMV vectors, but clearly these responses require expression
of a particular set of CMV genes (16), which may not be present in
MCMV85A.
Irrespective of the reason for the very low 85A-specific re-
sponse in the MCMV85A-infected animals, the data illustrate an
important principle, that it may not be necessary to induce a large
Ag-specific population to obtain effective protection. This is in
agreement with a recent study using an rMCMV virus containing
an HSV-1 epitope, which showed that it is not necessary to induce
an inflationary CD8 response for protection (13).
Our data indicate that in addition to the specificity andmagnitude
of the adaptive response, other factors may be critical for effective
protection againstM. tuberculosis. It is clear that MCMV itself has
a nonspecific protective effect against M. tuberculosis, as has al-
ready been shown for Listeria monocytogenes for both MCMV
(51) (P. Klenerman and G. O’Hara, personal communication) and
murine gammaherpesvirus 68 (52). However, this effect, attributed
to IFN-g production and macrophage activation, has been reported
to wane between 3 and 6 mo after virus infection (53), whereas
there was still a trend toward a decreased mycobacterial load in
eMCMV-infected mice at 24 wk (Fig. 1). It will be interesting to
examine protection induced by both eMCMV and MCMV85A at
even later time points after infection. Furthermore, although we
have not excluded an effect of macrophage activation, this is
largely dependent on MCK-2 in vivo, which is deficient in the
Dm1-16-FRT backbone (54).
MCMVinfection is known to efficiently activate NK cells, although
the magnitude of this effect varies substantially depending on the host
strain and virus variant (55, 56). Our microarray data indicate that the
IL-21 message is upregulated in eMCMV-infected BALB/c mice, and
we chose to investigate this gene further because it is known that
a prominent effect of this highly pleiotropic member of the common
g-chain cytokine family is NK cell activation (57). Furthermore,
pathway analysis showed that several genes related to IL-21 function
are also highly upregulated (AICDA, RGS13, IL-10, MADCAM1).
NK cell activation was confirmed by the increased NK cytotoxicity of
cells from eMCMV mice. The importance of IL-21 and NK cells
is supported by the in vivo experiments with IL-21RFc and
IL-21, as well as the abolition of nonspecific protection by admin-
istration of anti-ASGM1 Ab. Interestingly, a plasmid expressing
M. tuberculosis Ags 85A and ESAT-6 with IL-21 has been shown
to give increased immune responses to the M. tuberculosis Ags,
higher NK activity, and better protection against M. tuberculosis,
compared with a plasmid without IL-21 (58).
In addition to the nonspecific effect, the 85A-specific cells induced
by MCMV85A and recruited to or expanded in the lungs after
M. tuberculosis challenge must play a role in protection (Fig. 4C)
because MCMV85A consistently provides better protection than
eMCMV, although whether the activated NK cells play a role in the
activation of the Ag-specific CD8 cells remains to be determined.
As is the case with MCMV85A, BCG, the gold standard TB
vaccine, is known to activate the innate immune system as well as
induce an adaptive response (59). Furthermore, BCG induces a state
of “trained immunity” in macrophages, persisting for several
months and conferring increased nonspecific protection against
other infections (8, 60), and recently cytokine responses of NK cells
were identified as an effector mechanism induced by BCG (61).
Although the relative importance of innate and adaptive re-
sponses in BCG-induced protective immunity remains to be deter-
mined, in the case of MCMV85A, innate immunity appears to
play an important role, although clearly potentiated by a weak
adaptive response. However, even when a much more powerful
and readily detectable adaptive response is induced, correct in-
nate signaling remains crucial, as shown in experiments in which
Ad85A and VSV85A were delivered to the lungs. Both vectors
induce powerful, largely CD8, local immune responses, but
whereas Ad85A is protective against M. tuberculosis, VSV85A is
not, an outcome ascribed to a critical difference in the balance
between IL-12 and type I IFN induced by the two vaccines (9).
To our knowledge, we have demonstrated specific anti–M. tu-
berculosis protection for the first time using novel MCMV vectors.
Surprisingly, a small Ag-specific response may be highly effective
in synergy with the correct innate activation in this case involving
IL-21 and NK cells. There is clearly great scope for improving
further the efficacy of CMV vectors (16, 51). New approaches are
certainly required, because so far no vaccine against pathogens,
for which T cells are the protective mechanism, has been successful,
and the strategy of attempting to induce ever greater adaptive T cell
responses has so far failed (2). Our data support the view that it is
essential to induce correct innate as well as adaptive responses.
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